

Xphozah (tenapanor)
Effective 05/01/2024

Plan	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input checked="" type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit		
Specialty Limitations	This medication has been designated specialty and must be filled at a contracted specialty pharmacy.		
Contact Information	Medical and Specialty Medications		
	All Plans	Phone: 877-519-1908	Fax: 855-540-3693
	Non-Specialty Medications		
	All Plans	Phone: 800-711-4555	Fax: 844-403-1029
Exceptions	N/A		

Overview

Xphozah (tenapanor) is indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Coverage Guidelines

Authorization may be granted for members who are currently receiving requested medication, excluding when the product is obtained as samples or via manufacturer's patient assistance programs.

OR

Authorization may be granted when the following criteria are met:

1. The member has a diagnosis of hyperphosphatemia in chronic kidney disease
2. The member is on dialysis
3. Member has had trial and inadequate response, intolerance, or contraindication to TWO of the following:
 - a. Calcium carbonate
 - b. Calcium acetate
 - c. Lanthanum carbonate
 - d. Sevelamer carbonate
 - e. Sevelamer HCl

Continuation of Therapy

Reauthorization may be granted when provider attestation is submitted for members who achieve or maintain positive clinical response.

Limitations

1. Initial approvals and reauthorizations will be granted for 12 months.
2. The following quantity limits apply:

Xphozah 20mg and 30mg	60 tablets per month
-----------------------	----------------------

References

1. Xphozah [prescribing information]. Waltham, MA. Ardelyx Inc. October 2023.
2. UptoDate. Management of hyperphosphatemia in adults with chronic kidney disease. Available at: https://www.uptodate.com/contents/management-of-hyperphosphatemia-in-adults-with-chronic-kidneydisease?search=dialysis%20in%20chronic%20kidney%20disease&source=search_result&selectedTitle=4~150&usage_type=default&display_rank=4#H169682201. Accessed December 11, 2023.
3. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease—Mineral and Bone Disorder (CKD-MBD). Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340919/>. Accessed December 11, 2023.

Review History

4/10/2024 – Reviewed and Created for April P&T. Effective 5/1/2024

